2C-B (4-bromo-2,5-dimethoxyphenethylamine) is a synthetic psychedelic of the phenethylamine family, first synthesised by the chemist Alexander Shulgin in 1974 and documented in his book PiHKAL. It is structurally related to mescaline and acts as a partial agonist at serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors (Papaseit et al., 2018).
2C-B is notably dose-dependent. At lower doses many people describe warm, sensual, sociable, entactogen-like effects comparable to MDMA, while higher doses produce clearly psychedelic visuals and altered thinking. Research comparing it with other drugs found it produces perceptual changes like other psychedelics but with lower impairment and more pleasurable, MDMA-like qualities (Caudevilla-Gálligo et al., 2012). Effects typically last around 4–8 hours.
Because it is highly dose-sensitive — small differences of a few milligrams meaningfully change the experience — and is sometimes mis-sold or confused with other compounds, accurate weighing and testing are especially important. This page summarises its pharmacology, effects, and risks, drawing on peer-reviewed literature and established harm-reduction resources.